BIO International 2026

HBO Max’s “The Last of Us” captivated audiences with its gripping portrayal of a post-apocalyptic world ravaged by a fungal infection. While fictional, the threat posed by fungal pathogens is real.

Clinical trials for large-population diseases face persistent challenges and remain the most complex and resource-intensive steps in drug development.

For decades, the biotech innovation engine has produced extraordinary breakthroughs in cancer, rare diseases, and metabolic disorders. Yet across vast areas of medicine from preeclampsia to sarcopenia, dry eye disease, and neurodegeneration, progress has stalled.

The next evolution of AI in biopharma is already here – systems designed not just to analyze data but to make decisions.

Precision medicine has transformed oncology, but the next wave is unfolding in new therapeutic areas. The expansion into new areas promises enormous impact, yet the path forward is not straightforward.

Overall survival (OS) remains the gold standard endpoint in oncology trials, but the FDA’s August 2025 draft guidance highlights new complexities in assessing survival in an era of highly effective therapies, longer patient lifespans, and confounding crossover or subsequent treatments.

For decades, autoimmune disease therapy has been defined by one trade-off – suppressing the immune system to relieve symptoms. That paradigm is now breaking.

Artificial intelligence (AI) has become a widely used label across biotech companies positioning platforms for drug discovery and development.